Life Sciences R&D Strategy

A life-sciences R&D strategy allocates scarce R&D capital across a portfolio of programmes to maximise risk-adjusted value, using disciplined stage-gate governance. This template applies stage-gate go/no-go decisions at each phase, portfolio optimisation on risk-adjusted NPV (rNPV), and consistent, criteria-driven thresholds — concentrating investment where evidence supports it and killing weak programmes early (notably the Phase II choke point).